DK434187D0 - Injektionspraeparat omfattende i phospholipidpartikler indkapslede antifungale polyen-antibiotika - Google Patents

Injektionspraeparat omfattende i phospholipidpartikler indkapslede antifungale polyen-antibiotika

Info

Publication number: DK434187D0
Authority: DK; Denmark
Prior art keywords: antifungal; antibiotics; polyen; vesicles; injection preparation
Prior art date: 1986-08-21

Application number

DK434187A

Other languages

English (en)

Other versions

DK434187A (da

DK168982B1 (da

Inventor

Jill Adler-Moore

Ronald Carl Gamble

Richard Thomas Proffitt

Original Assignee

Vestar Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-08-21

Filing date

1987-08-20

Publication date

1987-08-20

1987-08-20 Application filed by Vestar Inc filed Critical Vestar Inc

1987-08-20 Publication of DK434187D0 publication Critical patent/DK434187D0/da

1988-02-22 Publication of DK434187A publication Critical patent/DK434187A/da

1994-07-25 Application granted granted Critical

1994-07-25 Publication of DK168982B1 publication Critical patent/DK168982B1/da

Links

230000000843 anti-fungal effect Effects 0.000 title abstract 4
229940121375 antifungal agent Drugs 0.000 title abstract 4
239000002245 particle Substances 0.000 title abstract 3
239000003242 anti bacterial agent Substances 0.000 title abstract 2
229940088710 antibiotic agent Drugs 0.000 title abstract 2
150000003904 phospholipids Chemical class 0.000 title abstract 2
238000002347 injection Methods 0.000 title 1
239000007924 injection Substances 0.000 title 1
206010017533 Fungal infection Diseases 0.000 abstract 2
208000031888 Mycoses Diseases 0.000 abstract 2
230000003115 biocidal effect Effects 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
150000004291 polyenes Chemical class 0.000 abstract 2
230000009885 systemic effect Effects 0.000 abstract 2
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
239000007983 Tris buffer Substances 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 1
229960003942 amphotericin b Drugs 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229960000988 nystatin Drugs 0.000 abstract 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 abstract 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
239000000243 solution Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nanotechnology (AREA)
Dispersion Chemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Crystallography & Structural Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK434187A 1986-08-21 1987-08-20 Fremgangsmåde til dannelse af små vesikler, der omfatter et phospholipid og indkapsler et antifungalt polyen-antibiotikum, og præparat dannet ved denne fremgangsmåde til anvendelse ved en fremgangsmåde til behandling af systemiske fungale infektioner DK168982B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US89906486A	1986-08-21	1986-08-21
US89906486		1986-08-21

Publications (3)

Publication Number	Publication Date
DK434187D0 true DK434187D0 (da)	1987-08-20
DK434187A DK434187A (da)	1988-02-22
DK168982B1 DK168982B1 (da)	1994-07-25

Family

ID=25410437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK434187A DK168982B1 (da)	1986-08-21	1987-08-20	Fremgangsmåde til dannelse af små vesikler, der omfatter et phospholipid og indkapsler et antifungalt polyen-antibiotikum, og præparat dannet ved denne fremgangsmåde til anvendelse ved en fremgangsmåde til behandling af systemiske fungale infektioner

Country Status (14)

Country	Link
US (1)	US5874104A (da)
EP (1)	EP0260811B1 (da)
JP (1)	JPH0615475B2 (da)
KR (1)	KR950013747B1 (da)
AT (1)	ATE66597T1 (da)
AU (1)	AU606880B2 (da)
CA (1)	CA1292184C (da)
DE (1)	DE3772498D1 (da)
DK (1)	DK168982B1 (da)
ES (1)	ES2051740T3 (da)
GR (1)	GR3002852T3 (da)
HK (1)	HK115393A (da)
IE (1)	IE60901B1 (da)
NO (1)	NO174833C (da)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2620028B2 (fr) *	1986-12-05	1994-02-25	Ire Celltarg Sa	Procede de preparation de microcristaux comportant a titre de substance active, notamment de l'amphotericine b, microcristaux obtenus et composition pharmaceutique en comprenant
CA1338736C (fr) *	1986-12-05	1996-11-26	Roger Baurain	Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
US4812312A (en) *	1987-03-03	1989-03-14	Board Of Regents Of The University Of Texas System	Liposome-incorporated nystatin
US6406713B1 (en)	1987-03-05	2002-06-18	The Liposome Company, Inc.	Methods of preparing low-toxicity drug-lipid complexes
US5616334A (en) *	1987-03-05	1997-04-01	The Liposome Company, Inc.	Low toxicity drug-lipid systems
CA1338702C (en) *	1987-03-05	1996-11-12	Lawrence D. Mayer	High drug:lipid formulations of liposomal- antineoplastic agents
US4999199A (en) *	1988-11-10	1991-03-12	Board Of Regents, The University Of Texas System	Pharmaceutical formulations: liposomes incorporating aromatic polyene antibiotics
ATE140622T1 (de) *	1989-11-27	1996-08-15	Nippon Shinyaku Co Ltd	Fettemulsion
AU1201192A (en) *	1991-01-14	1992-08-17	Board Of Regents, The University Of Texas System	Anti-hiv activity of liposomal nystatin and amphotericin b
EP0664130A1 (en) *	1991-10-25	1995-07-26	Senju Pharmaceutical Co., Ltd.	External preparation for treating hemorrhoidal diseases
JP2915296B2 (ja) *	1993-08-30	1999-07-05	宇野潤	抗真菌製剤
GB9519654D0 (en) *	1995-09-27	1995-11-29	Nycomed Imaging As	Stabilised phospholipid compositions
DK0876140T3 (da) *	1996-01-25	2003-12-15	Schering Ag	Forbedrede kontrastmiddelopløsninger til intravasal anvendelse
GB9721901D0 (en) *	1997-10-16	1997-12-17	Univ Manchester	Particles
WO1999027940A1 (en) *	1997-12-01	1999-06-10	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Formulations for topical treatment of skin infections
IT1301807B1 (it) *	1998-06-25	2000-07-07	Tiberio Bruzzese	Formulazioni farmaceutiche iniettabili di derivati della partricina.
US6613352B2 (en)	1999-04-13	2003-09-02	Universite De Montreal	Low-rigidity liposomal formulation
US6413537B1 (en)	2000-03-10	2002-07-02	Wisconsin Alumni Research Foundation	Nystatin formulation having reduced toxicity
JP4786041B2 (ja) *	2001-03-02	2011-10-05	丸善製薬株式会社	渋味、収斂味を低減する方法および渋味、収斂味低減ハス胚芽抽出物製剤
US7651689B2 (en) *	2002-11-15	2010-01-26	Albert Einstein College Of Medicine Of Yeshiva University	Methods of applying ionization radiation for therapy of infections
US7846445B2 (en) *	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
EP1929073A4 (en) *	2005-09-27	2010-03-10	Amunix Inc	PROTEIN MEDICAMENT AND ITS USE
US20090099031A1 (en) *	2005-09-27	2009-04-16	Stemmer Willem P	Genetic package and uses thereof
US7855279B2 (en) *	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
WO2007056457A2 (en)	2005-11-09	2007-05-18	Combinatorx, Incorporated	Methods, compositions, and kits for the treatment of medical conditions
JP5738516B2 (ja)	2005-12-30	2015-06-24	ゼンサン（シャンハイ）サイエンスアンドテクノロジーリミテッド	心機能改善のためのニューレグリンの徐放
US8933197B2 (en) *	2007-08-15	2015-01-13	Amunix Operating Inc.	Compositions comprising modified biologically active polypeptides
CN102014927A (zh)	2008-03-06	2011-04-13	安纳考尔医药公司	作为抗炎药的含硼的小分子
CA2748314C (en)	2009-02-03	2018-10-02	Amunix Operating Inc.	Extended recombinant polypeptides and compositions comprising same
JP5839597B2 (ja)	2009-06-08	2016-01-06	アムニクスオペレーティングインコーポレイテッド	グルコース調節ポリペプチド並びにその作成及び使用方法
SI2440241T1 (sl)	2009-06-08	2017-11-30	Amunix Operating Inc.	Polipeptidni rastni hormoni in postopki za njihovo izdelavo in uporabo
JP6205133B2 (ja)	2009-07-10	2017-09-27	プレジデントアンドフェローズオブハーバードカレッジ	抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
AU2010290131C1 (en)	2009-08-24	2015-12-03	Amunix Operating Inc.	Coagulation factor VII compositions and methods of making and using same
BRPI1003990B1 (pt) *	2009-10-16	2021-09-14	Lifecare Innovations Pvt. Ltd	Formulação para o tratamento de infecções fúngicas
NZ599543A (en)	2009-10-30	2014-02-28	Ntf Therapeutics Inc	Improved neurturin molecules
WO2011075688A1 (en)	2009-12-18	2011-06-23	Exodos Life Sciences Limited Partnership	Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
US8716478B2 (en)	2010-01-27	2014-05-06	Anacor Pharmaceuticals, Inc.	Boron-containing small molecules
EP2668961A4 (en)	2010-11-19	2016-07-06	Univ Sapporo Medical	PHARMACEUTICAL COMBINATION PREPARATION
BR112014020694A2 (pt)	2012-02-15	2018-05-08	Amunix Operating Inc.	proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
CA2864126A1 (en)	2012-02-15	2013-08-22	Biogen Idec Ma Inc.	Recombinant factor viii proteins
RS61391B1 (sr)	2012-06-08	2021-02-26	Alkermes Pharma Ireland Ltd	Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti
US10548953B2 (en)	2013-08-14	2020-02-04	Bioverativ Therapeutics Inc.	Factor VIII-XTEN fusions and uses thereof
JP6608422B2 (ja)	2014-03-25	2019-11-20	ザガバメントオブザユナイテッドステイツ，アズリプリゼンティッドバイザセクレタリーオブジアーミー	モノホスホリルリピッドａ（ｍｐｌａ）含有リポソーム組成物およびサポニンを含む非毒性アジュバント製剤
EP3226972A4 (en)	2014-12-01	2018-08-08	Achelios Therapeutics, Inc.	Methods and compositions for treating migraine and conditions associated with pain
AU2016301282B2 (en)	2015-08-03	2022-03-17	Children's Medical Center Corporation	Charged ion channel blockers and methods for use
BR112018002150A2 (pt)	2015-08-03	2018-09-18	Bioverativ Therapeutics Inc	proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
CA3003483C (en)	2015-11-06	2022-09-13	Adjuvance Technologies, Inc.	Triterpene saponin analogues
JP2019532027A (ja)	2016-08-17	2019-11-07	ソルスティスバイオロジクス，リミティッド	ポリヌクレオチド構築物
IL319473A (en)	2016-12-02	2025-05-01	Bioverativ Therapeutics Inc	Methods for treating hemophilic arthritis using chimeric blood clotting factors
EP3618836A4 (en)	2017-04-25	2021-01-13	Adjuvance Technologies, Inc.	TRITERPENSAPONINALOGA
WO2019006455A1 (en)	2017-06-30	2019-01-03	Solstice Biologics, Ltd.	AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
WO2019079160A1 (en)	2017-10-16	2019-04-25	Adjuvance Technologies, Inc.	TRITERPENIC SAPONIN ANALOGS
BR112020022164A2 (pt)	2018-05-18	2021-02-02	Bioverativ Therapeutics Inc.	métodos de tratamento de hemofilia a
US10780083B1 (en)	2019-03-11	2020-09-22	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
CN113811305A (zh)	2019-03-11	2021-12-17	诺西恩医疗公司	带电的离子通道阻滞剂及其使用方法
AU2020234961C1 (en)	2019-03-11	2025-08-14	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
BR112021017809A2 (pt)	2019-03-11	2021-11-23	Nocion Therapeutics Inc	Bloqueadores de canais iônicos substituídos por éster e métodos para uso
US10786485B1 (en)	2019-03-11	2020-09-29	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
CA3139559A1 (en)	2019-05-09	2020-11-12	Apkarian Technologies Llc	Methods and compositions for treating pain
EP4021934A4 (en)	2019-08-30	2024-02-14	The Regents of the University of California	Gene fragment overexpression screening methodologies, and uses thereof
WO2021091586A1 (en)	2019-11-06	2021-05-14	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
WO2021091585A1 (en)	2019-11-06	2021-05-14	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
US12162851B2 (en)	2020-03-11	2024-12-10	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
US11332446B2 (en)	2020-03-11	2022-05-17	Nocion Therapeutics, Inc.	Charged ion channel blockers and methods for use
JP2023531494A (ja)	2020-06-25	2023-07-24	アムニクスファーマシューティカルズ，インコーポレイテッド	Ｈｅｒ－２標的化二重特異性組成物ならびにその作製および使用のための方法
IL306074A (en)	2021-03-24	2023-11-01	Alkermes Inc	UPAR antibodies and fusion proteins with them
EP4493153A1 (en)	2022-03-14	2025-01-22	Pfizer Inc.	Methods for producing an adjuvant
KR20240164801A (ko)	2022-03-21	2024-11-20	더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈	암포테리신 b의 지질-코팅된 결정을 포함하는 이온 채널 보형 조성물
IL321069A (en)	2022-12-01	2025-07-01	Pfizer	Pneumococcal conjugate vaccine preparations
WO2025057058A1 (en)	2023-09-13	2025-03-20	Pfizer Inc.	Methods for producing an adjuvant
TW202602467A (zh)	2024-03-11	2026-01-16	美商輝瑞股份有限公司	包含經共軛之大腸桿菌糖的免疫原性組成物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4310505A (en) *	1979-11-08	1982-01-12	California Institute Of Technology	Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4497791A (en) *	1983-02-10	1985-02-05	Vestar Research Incorporated	Method for labeling phagocytic cells
GB2135647A (en) *	1983-02-15	1984-09-05	Squibb & Sons Inc	Method of preparing liposomes and products produced thereby
PT78628B (en) *	1984-05-02	1986-06-18	Liposome Co Inc	Pharmaceutical composition with reduced toxicity
US4880635B1 (en) *	1984-08-08	1996-07-02	Liposome Company	Dehydrated liposomes
IE58659B1 (en) *	1984-10-22	1993-11-03	Vestar Inc	Use of a micellular particle composition encapsulating a chemotherapeutic agent for intravenous targeting to tumors
US4753788A (en) *	1985-01-31	1988-06-28	Vestar Research Inc.	Method for preparing small vesicles using microemulsification
US4766046A (en) *	1985-09-27	1988-08-23	Liposome Technology, Inc.	Stabilized liposome/amphotericin composition and method
US4812312A (en) *	1987-03-03	1989-03-14	Board Of Regents Of The University Of Texas System	Liposome-incorporated nystatin

1987
- 1987-08-11 IE IE214887A patent/IE60901B1/en not_active IP Right Cessation
- 1987-08-14 ES ES87307221T patent/ES2051740T3/es not_active Expired - Lifetime
- 1987-08-14 AT AT87307221T patent/ATE66597T1/de not_active IP Right Cessation
- 1987-08-14 EP EP87307221A patent/EP0260811B1/en not_active Expired - Lifetime
- 1987-08-14 DE DE8787307221T patent/DE3772498D1/de not_active Expired - Lifetime
- 1987-08-18 AU AU77160/87A patent/AU606880B2/en not_active Expired
- 1987-08-19 CA CA000544830A patent/CA1292184C/en not_active Expired - Lifetime
- 1987-08-19 NO NO873492A patent/NO174833C/no not_active IP Right Cessation
- 1987-08-20 KR KR1019870009101A patent/KR950013747B1/ko not_active Expired - Lifetime
- 1987-08-20 DK DK434187A patent/DK168982B1/da not_active IP Right Cessation
- 1987-08-21 JP JP62208049A patent/JPH0615475B2/ja not_active Expired - Fee Related
1991
- 1991-10-08 GR GR91401494T patent/GR3002852T3/el unknown
1993
- 1993-10-28 HK HK1153/93A patent/HK115393A/en not_active IP Right Cessation
1995
- 1995-06-06 US US08/467,864 patent/US5874104A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
HK115393A (en)	1993-11-05
NO873492L (no)	1988-02-22
AU606880B2 (en)	1991-02-21
EP0260811B1 (en)	1991-08-28
ES2051740T3 (es)	1994-07-01
KR880002531A (ko)	1988-05-09
US5874104A (en)	1999-02-23
AU7716087A (en)	1988-02-25
JPS6366123A (ja)	1988-03-24
IE60901B1 (en)	1994-08-24
DK434187A (da)	1988-02-22
ATE66597T1 (de)	1991-09-15
NO174833B (no)	1994-04-11
JPH0615475B2 (ja)	1994-03-02
IE872148L (en)	1988-02-21
EP0260811A3 (en)	1988-07-20
CA1292184C (en)	1991-11-19
GR3002852T3 (en)	1993-01-25
KR950013747B1 (ko)	1995-11-15
NO174833C (no)	1994-07-20
NO873492D0 (no)	1987-08-19
EP0260811A2 (en)	1988-03-23
DE3772498D1 (de)	1991-10-02
DK168982B1 (da)	1994-07-25

Legal Events

Date	Code	Title	Description
2007-09-10	PUP	Patent expired

Publication	Publication Date	Title
DK434187D0 (da)	1987-08-20	Injektionspraeparat omfattende i phospholipidpartikler indkapslede antifungale polyen-antibiotika
BR1100687A (pt)	2000-02-08	Formulações de agentes antineoplásticos lipossÈmicos com proporção elevada de droga com lipìdio
AU587232B2 (en)	1989-08-10	Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles and methods for using same for tumor therapy
KR890007718A (ko)	1989-07-05	개선된 암포테리신b 리포좀 제조법
GR1000074B (el)	1990-10-31	Λιποειδη σφαιριδια (κυστιδια) για ενδοπεριτονειακη χορηγηση θεραπευτικων παραγοντων.
NO180147C (no)	1997-02-26	Fremgangsmåte for fremstilling av HDLC eller et liposom innbefattende et polyen-antisopp-antibiotikum og et lipid
ATE186835T1 (de)	1999-12-15	Herstellung von formulierungen zur arzneiverabreichung mittels elektrotransport
KR950700725A (ko)	1995-02-20	리포솜 조성물(liposome composition)
DK32388A (da)	1988-07-28	Phospholipid-baeremiddel for vand-uoploeselige aktive bestanddele